Literature DB >> 15864383

So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity.

Anthony Chang1, Scott M Schuetze, Ernest U Conrad, Karen L Swisshelm, Thomas H Norwood, Brian P Rubin.   

Abstract

Inflammatory leiomyosarcoma, a rare entity first described in 1995, has been characterized by smooth muscle differentiation, a near-haploid karyotype, and a surprisingly good prognosis. The morphology is similar to that of conventional leiomyosarcoma admixed with a chronic inflammatory infiltrate. Thus far, only 15 cases have been reported in the English language literature. We report the clinical and pathological features of 3 additional cases of inflammatory leiomyosarcoma. Two women (ages 64 and 25, respectively) and 1 man (age 32) presented with a thigh, ovary, and lung mass, respectively. Inflammatory symptoms, such as anorexia, fever, night sweats, abdominal pain, and diarrhea, coincided with the thigh and ovarian primaries. Immunohistochemical studies revealed diffuse positivity for desmin and poor expression for other smooth muscle and skeletal muscle markers (muscle-specific actin [0/3], alpha-smooth muscle actin 1/3 [focal], calponin [1/3], caldesmon [0/3], and myogenin [0/3]). CD68 was diffusely positive in both the histiocytes and spindle cell component in all cases. Ultrastructural evaluation of 1 case (lung primary) lacked definitive smooth muscle differentiation. Cytogenetic analysis in 1 of 2 cases that were karyotyped, identified a near-haploid karyotype, which has been reported in other cases of inflammatory leiomyosarcoma. The other case showed 2 clonal populations of cells with interstitial deletions of the short arm of chromosome 8 and the long arm of chromosome 9, respectively. The case without cytogenetic data was intimately associated with an ovarian mature teratoma. These data also suggest that inflammatory leiomyosarcoma may lack smooth muscle differentiation, characterized by diffuse immunoreactivity for desmin but lack of immunoreactivity for alpha-smooth muscle actin, calponin, and caldesmon. In addition, 2 of the 3 cases developed distant metastases to the lungs, which suggests that these lesions may have a worse prognosis than previously believed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864383     DOI: 10.1177/106689690501300210

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  6 in total

1.  Retained heterodisomy is associated with high gene expression in hyperhaploid inflammatory leiomyosarcoma.

Authors:  Karolin H Nord; Kajsa Paulsson; Srinivas Veerla; Johan Wejde; Otte Brosjö; Nils Mandahl; Fredrik Mertens
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

Review 2.  WHO Pathology: Highlights of the 2020 Sarcoma Update.

Authors:  Inga-Marie Schaefer; Alessandro Gronchi
Journal:  Surg Oncol Clin N Am       Date:  2022-05-31       Impact factor: 2.402

Review 3.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

4.  Inflammatory leiomyosarcoma is a distinct tumor characterized by near-haploidization, few somatic mutations, and a primitive myogenic gene expression signature.

Authors:  Elsa Arbajian; Jan Köster; Fredrik Vult von Steyern; Fredrik Mertens
Journal:  Mod Pathol       Date:  2017-09-08       Impact factor: 7.842

5.  Inflammatory leiomyosarcoma/rhabdomyoblastic tumor: A report of two cases with novel genetic findings.

Authors:  Madina Sukhanova; Farres Obeidin; Lukas Streich; Borislav A Alexiev
Journal:  Genes Chromosomes Cancer       Date:  2022-06-30       Impact factor: 4.263

6.  Genome-wide acquired uniparental disomy as well as chromosomal gains and losses in an uterine epithelioid leiomyoma.

Authors:  Carsten Holzmann; Dominique Nadine Markowski; Dirk Koczan; Burkhard Maria Helmke; Jörn Bullerdiek
Journal:  Mol Cytogenet       Date:  2014-03-03       Impact factor: 2.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.